A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.

Publication Type:

Journal Article

Source:

Blood cancer journal, Volume 6, p.e422 (2016)